Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

RxNews Recap for Friday 01-29-10

Below is a list of the companies that made news in the healthcare sector on Friday, January 29, 2010.

Conceptus, Inc. (NASDAQ:CPTS), developer of the Essure® procedure, today announced that the Company will introduce 2010 guidance and release 2009 fourth quarter financial results on Tuesday, February 23, 2010 after the close of market.

Enzo Biochem, Inc. (NYSE: ENZ) is well positioned to benefit from the results of its transformation involving acquisitions, new managements at each of its major subsididries and a heightened focus on new life science, diagnostic and therapeutic products, Barry Weiner, President, told the annual meeting of shareholders today.

Genzyme Corporation (NASDAQ: GENZ) announced today that it has taken steps to strengthen the role of its lead independent director, and appointed new leadership to head the board’s audit committee.

Gilead Sciences, Inc. (Nasdaq:GILD) today announced that the company’s Board of Directors has authorized the repurchase of up to $1.0 billion of the company’s common stock through January 2011.

Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) (the "Company") today announced that an article entitled "Clinical and Translational Studies of a Phase II Trial of the Novel Oral Akt Inhibitor Perifosine in Relapsed or Relapsed/Refractory Waldenstrom's Macroglobulinemia," reporting Phase 2 data demonstrating the single agent activity of KRX-0401 (Perifosine) for the treatment of advanced Waldenstrom's Macroglobulinemia ("Waldenstrom's"), will appear in the February 1, 2010 issue of Clinical Cancer Research.  

Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (NASDAQ:ANDA) for Polyethylene Glycol 3350 and Electrolytes for Oral Solution, USP, the generic version of Braintree Laboratories' GoLytely® laxative.

PROLOR Biotech, Inc., (OTC Bulletin Board: PBTH) today noted the European Commission (NYSE:EC) approval of Merck & Co., Inc.'s ELONVA®, a long-acting CTP-modified version of the fertility drug follicle stimulating hormone (FSH).  With the EC approval, Merck has marketing authorization for ELONVA with unified labeling valid in all European Union Member States.  

QuantRx Biomedical Corporation (OTCBB: QTXB) today announced that it has entered into an agreement to acquire NuRx Pharmaceuticals, Inc. (OTCBB: NUXP).

Quidel Corporation (NASDAQ:QDEL), a leading provider of rapid point-of-care (POC) diagnostic tests, will release fourth quarter and full year 2009 financial results after market close on Thursday, February 11, 2010.

Repligen Corporation (Nasdaq: RGEN) announced today that the Company President and Chief Executive Officer, Walter C. Herlihy, Ph.D., will host a conference call and webcast on Thursday, February 4th, 2010 at 10:00 a.m. EST, to report third quarter fiscal year 2010 financial results and to provide a quarterly update of the Company.

Rosetta Genomics (NASDAQ:ROSG) today announced that the United States Patent and Trademark Office has allowed claims in two patent applications.

Senomyx, Inc. (NASDAQ: SNMX), a leading company focused on using proprietary technologies to discover and develop novel flavor ingredients for the food, beverage, and ingredient supply industries, announced today that Firmenich SA, the world's largest privately-owned fragrance and flavor company, has made a decision to proceed with commercial development of S6973, Senomyx’s enhancer of sucrose (table sugar) that has demonstrated the ability to reduce up to 50% of the sugar in a variety of products while maintaining the taste of natural sugar.

As required under the indenture covering Apogent Technologies Inc. Floating Rate Convertible Senior Debentures due 2033 (CUSIP No. 03760AAK7), Thermo Fisher Scientific Inc. (NYSE: TMO) is providing public notice to the holders of these bonds that they have the right to receive contingent interest for the current quarterly interest period ending March 15, 2010.